ACRS – aclaris therapeutics, inc. (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Days Volatility
Open
Prior Close

YTD

1 Day

ACRS

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

4/8

08:30 am

acrs

Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference

Low Report

Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference

Report

3/31

10:20 am

acrs

Aclaris Therapeutics (ACRS) had its "outperform" rating reaffirmed by Wedbush. They now have a $8.00 price target on the stock.

Low Report

Aclaris Therapeutics (ACRS) had its "outperform" rating reaffirmed by Wedbush. They now have a $8.00 price target on the stock.

Report

3/27

10:10 am

acrs

Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138

Low Report

Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138

Report

3/20

11:00 am

acrs

Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting

Low Report

Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting

Report

3/19

08:22 am

acrs

Aclaris Therapeutics (ACRS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $16.00 price target on the stock.

Medium Report

Aclaris Therapeutics (ACRS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $16.00 price target on the stock.

Report

3/18

07:05 am

acrs

Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis [Yahoo! Finance]

Low Report

Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis [Yahoo! Finance]

Report

3/18

06:55 am

acrs

Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

Low Report

Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

Report

3/10

03:12 pm

acrs

Aclaris Therapeutics Highlights Atopic Dermatitis Data Catalysts, ITK Progress at Leerink Conference [Yahoo! Finance]

Neutral Report

Aclaris Therapeutics Highlights Atopic Dermatitis Data Catalysts, ITK Progress at Leerink Conference [Yahoo! Finance]

Report

Date

Time

Symbol

Company Name

Action

%Chg

2/26/2026

06:58 am

acrs

aclaris therapeutics, inc.

MISS Report

-7.8%

aclaris therapeutics, inc.

Report

11/6/2025

06:59 am

acrs

aclaris therapeutics, inc.

BEAT Report

0.4%

aclaris therapeutics, inc.

Report

8/7/2025

06:59 am

acrs

aclaris therapeutics, inc.

IN-LINE Report

1.3%

aclaris therapeutics, inc.

Report

5/8/2025

06:50 am

acrs

aclaris therapeutics, inc.

BEAT Report

7.4%

aclaris therapeutics, inc.

Report

Date

Time

Action

From

Firm

Impact

%Chg

3/31

10:20 am

Reiterates

Outperform

Wedbush

Low

Report

2.3%

Report

3/31

10:20 am

Reiterates

Outperform

Wedbush

Low

Report

2.3%

Report

3/31

09:59 am

Reiterates

Outperform

Wedbush

Low

Report

2.7%

Report

3/31

09:59 am

Reiterates

Outperform

Wedbush

Low

Report

2.7%

Report

3/19

08:22 am

Reiterates

Buy

HC Wainwright

Medium

Report

5.6%

Report

2/3

07:12 am

Upgrades

Strong-Buy

Craig Hallum

Low

Report

-2.0%

Report

2/3

07:12 am

Upgrades

Strong-Buy

Craig Hallum

Low

Report

-2.0%

Report

1/30

08:14 am

Initiates

Buy

Craig Hallum

Low

Report

-1.7%

Report

Date

Time

Symbol

Headline

Impact

4/7

06:00 pm

acrs

Form SCHEDULE 13G Aclaris Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Medium Report

Form SCHEDULE 13G Aclaris Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Report

3/26

03:06 pm

acrs

Form SCHEDULE 13G/A Aclaris Therapeutics, Filed by: VANGUARD GROUP INC

Low Report

Form SCHEDULE 13G/A Aclaris Therapeutics, Filed by: VANGUARD GROUP INC

Report

3/17

04:17 pm

acrs

Form SCHEDULE 13G Aclaris Therapeutics, Filed by: Deep Track Capital, LP

Medium Report

Form SCHEDULE 13G Aclaris Therapeutics, Filed by: Deep Track Capital, LP

Report

3/11

04:31 pm

acrs

Form 8-K Aclaris Therapeutics, For: Mar 10

Medium Report

Form 8-K Aclaris Therapeutics, For: Mar 10

Report

3/10

06:03 am

acrs

Form 8-K Aclaris Therapeutics, For: Mar 09

Medium Report

Form 8-K Aclaris Therapeutics, For: Mar 09

Report

3/3

04:15 pm

acrs

Form 4 Aclaris Therapeutics, For: Mar 01 Filed by: Balthaser Kevin

Low Report

Form 4 Aclaris Therapeutics, For: Mar 01 Filed by: Balthaser Kevin

Report

2/26

04:32 pm

acrs

Form 10-K Aclaris Therapeutics, For: Dec 31

Medium Report

Form 10-K Aclaris Therapeutics, For: Dec 31

Report

2/26

07:15 am

acrs

Form 8-K Aclaris Therapeutics, For: Feb 26

Low Report

Form 8-K Aclaris Therapeutics, For: Feb 26

Report

Stock Stats

News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings

Order Stats
Sub-Penny

Odd lot

Avg. bid-ask spread

Avg. bid-ask size

Shares at ask/bid

Off exchange

Main News & Impact Reports

Don’t Miss Out On The Next BIG Stock Move

Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.